Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
79.8 USD +0.80% Intraday chart for Axsome Therapeutics, Inc. -1.31% +0.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating MT
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment MT
Transcript : Axsome Therapeutics, Inc. - Special Call
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy CI
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108 MT
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder CI
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept MT
Sector Update: Health Care Stocks Lower Late Afternoon MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon MT
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises; Shares Drop MT
Transcript : Axsome Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q4 Revenue $71.5M, vs. Street Est of $69M MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Axsome Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Earnings Back in -2- DJ
Mizuho Raises PT on Axsome Therapeutics to $112 From $90 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
Chart Axsome Therapeutics, Inc.
More charts
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
79.8 USD
Average target price
121.2 USD
Spread / Average Target
+51.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Axsome Therapeutics, Inc. - Nasdaq
  4. News Axsome Therapeutics, Inc.
  5. Axsome Therapeutics : SMBC Nikko Initiates Axsome Therapeutics With Outperform Rating, $165 Price Target